EUVIMEDEUVIMED entdecken
Crossref

Generation and Biological Characterization of an Anti‐IL‐6Rα Biosimilar Candidate Antibody

Gisela García-Pérez, Gabriela García-Entenza, Arlem García Delgado, Arnelys Durán-Hernández, Tania Gómez Peña iD, Roberto Daniel Machado-Santisteban, Gertrudis Rojas, Tania Carmenate

Biotechnology Journal · 2025

DOI: 10.1002/biot.70017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Journal, 2025. Verfasst von Gisela García-Pérez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Immune Regulation Department, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Receptors, Interleukin-6, Biosimilar Pharmaceuticals. Die Arbeit nennt 64 Literaturangaben. Gefördert von: Center of Molecular Immunology., G.R. Alexander von Humboldt Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tocilizumab is a monoclonal antibody (mAb) that recognizes human Interleukin 6 receptor alpha (IL‐6Rα) and antagonizes IL‐6 signaling. It is therefore used in the treatment of moderate to severe rheumatoid arthritis in patients with inadequate response to antirheumatic drugs, and in the treatment of systemic juvenile idiopathic arthritis. During the course of the Coronavirus Disease 2019 (COVID‐19) pandemic, the potential application of Tocilizumab in severe inflammatory diseases was demonstrated. In addition, the drug is attracting increasing attention for its potential application in other pathologies, particularly cancers where the central role of Interleukin 6 (IL‐6) has been described, such as pancreatic ductal adenocarcinoma. The necessity for further research in this area is far too great, which is why the development of additional biosimilars is both necessary and welcome. In this work, we describe the generation and biological characterization of a biosimilar candidate of Tocilizumab. A stable producing CHO‐K1 cell line was obtained by lentiviral transduction. We demonstrated that the antibody generated, named 41TB, has similar size heterogeneity and electrophoretic profile as Tocilizumab, and high levels of purity. Moreover, 41TB exhibits comparable binding capacity to IL‐6Rα, as well as the ability to interrupt IL‐6/IL‐6Rα binding in ELISA. Additionally, both antibodies were likewise able to inhibit DS‐1 cell proliferation, IL‐6 induced STAT3 phosphorylation, and C‐Reactive Protein production in vitro. Galactose supplementation of the culture medium appears to be necessary to generate a glycosylation profile similar to the original antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedReceptors, Interleukin-6Biosimilar PharmaceuticalsCHO CellsCricetulusHumansAnimalsInterleukin-6SARS-CoV-2COVID-19STAT3 Transcription Factor

Stichwörter der Autor:innen

CHO‐K1IL‐6IL‐6RαTocilizumabbiosimilarlentivirusmAb

Substanzen

Antibodies, Monoclonal, HumanizedReceptors, Interleukin-6Biosimilar PharmaceuticalstocilizumabInterleukin-6interleukin-6 receptor alphaSTAT3 Transcription Factor

Autor:innen und Institutionen

  • Immune Regulation Department, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba.
  • Bioprocess R&D Direction, Center of Molecular Immunology, Havana, Cuba.
  • Quality Direction, Center of Molecular Immunology, Havana, Cuba.
  • Protein Engineering Department, Immunology and Immunotherapy Direction, Center of Molecular Immunology, Havana, Cuba.

ORCID-Profile: Tania Gómez Peña

Förderung

  • Center of Molecular Immunology.
  • G.R. Alexander von Humboldt Foundation

Zitieren

APA

García-Pérez, G., García-Entenza, G., Delgado, A. G., Durán-Hernández, A., Peña, T. G., Machado-Santisteban, R. D., Rojas, G., & Carmenate, T. (2025). Generation and Biological Characterization of an Anti‐IL‐6Rα Biosimilar Candidate Antibody. Biotechnology Journal. https://doi.org/10.1002/biot.70017

Vancouver

García-Pérez G, García-Entenza G, Delgado AG, Durán-Hernández A, Peña TG, Machado-Santisteban RD, et al. Generation and Biological Characterization of an Anti‐IL‐6Rα Biosimilar Candidate Antibody. Biotechnology Journal. 2025. doi:10.1002/biot.70017

BibTeX
@article{GarcaPrez2025,
  author = {García-Pérez, Gisela and García-Entenza, Gabriela and Delgado, Arlem García and Durán-Hernández, Arnelys and Peña, Tania Gómez and Machado-Santisteban, Roberto Daniel and Rojas, Gertrudis and Carmenate, Tania},
  title = {Generation and Biological Characterization of an Anti‐IL‐6Rα Biosimilar Candidate Antibody},
  journal = {Biotechnology Journal},
  year = {2025},
  doi = {10.1002/biot.70017}
}
Kostenlos starten →